Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans G Kress

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Journal of Pain & Palliative Care Pharmacotherapy|May 22, 2013
The importance of putting pain on the curricula in medical schools in EuropeHans G Kress
European Journal of Pain (London, England)|June 24, 2008
Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphineHans G Kress
European Journal of Pain (London, England)|July 28, 2010
Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?Hans G Kress
The Journal of Pharmacology and Experimental Therapeutics|August 2, 2005
Indirect CB2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoidsBirgit Kraft, Hans G Kress
American Journal of Physical Medicine & Rehabilitation|December 21, 2012
No (rehabilitation) gain without pain (management)Hans G Kress, Roberto Casale
European Journal of Pain (London, England)|March 2, 2005
Opioid medication and driving abilityHans G Kress, Birgit Kraft
European Journal of Pain (London, England)|March 2, 2005
Opioids for chronic nonmalignant and neuropathic painJürgen Sandkühler, Hans G Kress
Journal of Pain Research|June 14, 2019
Tapentadol in the management of cancer pain: current evidence and future perspectivesHans G Kress, Flaminia Coluzzi
Journal of Pain Research|June 14, 2019
Tapentadol: a new option for the treatment of cancer and noncancer painsAnthony H Dickenson, Hans G Kress
Life Sciences|June 15, 2004
Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamideBirgit Kraft, Winfried Wintersberger, Hans G Kress
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Journal of Pain & Palliative Care Pharmacotherapy|May 22, 2013
The importance of putting pain on the curricula in medical schools in EuropeHans G Kress
European Journal of Pain (London, England)|June 24, 2008
Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphineHans G Kress
European Journal of Pain (London, England)|July 28, 2010
Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?Hans G Kress
The Journal of Pharmacology and Experimental Therapeutics|August 2, 2005
Indirect CB2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoidsBirgit Kraft, Hans G Kress
American Journal of Physical Medicine & Rehabilitation|December 21, 2012
No (rehabilitation) gain without pain (management)Hans G Kress, Roberto Casale
European Journal of Pain (London, England)|March 2, 2005
Opioid medication and driving abilityHans G Kress, Birgit Kraft
European Journal of Pain (London, England)|March 2, 2005
Opioids for chronic nonmalignant and neuropathic painJürgen Sandkühler, Hans G Kress
Journal of Pain Research|June 14, 2019
Tapentadol in the management of cancer pain: current evidence and future perspectivesHans G Kress, Flaminia Coluzzi
Journal of Pain Research|June 14, 2019
Tapentadol: a new option for the treatment of cancer and noncancer painsAnthony H Dickenson, Hans G Kress
Life Sciences|June 15, 2004
Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamideBirgit Kraft, Winfried Wintersberger, Hans G Kress
Pageof 3